| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/28/2013 | US20130053433 Fatty acid derivatives and analogs of drugs |
| 02/28/2013 | US20130053431 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 02/28/2013 | US20130053419 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| 02/28/2013 | US20130053418 Acyclic organonitro compounds for use in treating cancer |
| 02/28/2013 | US20130053415 Combination methods for treatment of disease |
| 02/28/2013 | US20130053414 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 02/28/2013 | US20130053412 Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| 02/28/2013 | US20130053410 Substituted heteroaryl 2',3',7',7a'-tetrahydrospiro[pyrrole-3,6'-pyrrolo[1,2-c]imidazole]-1',2(1h,5'h)-dione |
| 02/28/2013 | US20130053409 2-(2,4,5-substituted-anilino) pyrimidine compounds |
| 02/28/2013 | US20130053408 Methods and compositions utilizing quinazolinones |
| 02/28/2013 | US20130053407 Pyrrolo [3,2-d] pyrimidin-3-yl derivatives used as activators of ampk |
| 02/28/2013 | US20130053406 Therapeutic compounds and uses thereof |
| 02/28/2013 | US20130053401 Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof |
| 02/28/2013 | US20130053398 Modulators of fatty acid amide hydrolase |
| 02/28/2013 | US20130053397 Indoles |
| 02/28/2013 | US20130053396 Piperidine and piperazine derivatives as smo antagonists |
| 02/28/2013 | US20130053395 Pyrazolopyridine kinase inhibitors |
| 02/28/2013 | US20130053394 Pyrazolopyrimidine kinase inhibitors |
| 02/28/2013 | US20130053392 Carbonic anhydrase inhibitors |
| 02/28/2013 | US20130053391 Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin |
| 02/28/2013 | US20130053390 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives |
| 02/28/2013 | US20130053388 Pyrazolopyrazine kinase inhibitors |
| 02/28/2013 | US20130053384 Certain Chemical Entities, Compositions, and Methods |
| 02/28/2013 | US20130053383 Indazoles |
| 02/28/2013 | US20130053382 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| 02/28/2013 | US20130053379 4-aryl-2-anilino-pyrimidines |
| 02/28/2013 | US20130053376 Novel tyrosine kinase inhibitors |
| 02/28/2013 | US20130053372 5-ht receptor modulators |
| 02/28/2013 | US20130053371 Inhibitors of pi3 kinase |
| 02/28/2013 | US20130053370 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES |
| 02/28/2013 | US20130053365 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/28/2013 | US20130053362 Heterocyclic compounds and uses thereof |
| 02/28/2013 | US20130053356 2-methylene-19,23,24-trinor-1alpha-hydroxyvitamin d3 |
| 02/28/2013 | US20130053351 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| 02/28/2013 | US20130053347 Pro-drugs of amaryllidaceae isocarbostyril products and their use against brain tumors |
| 02/28/2013 | US20130053344 Synthesis of pyrrolidine compounds |
| 02/28/2013 | US20130053343 Compounds and methods for inhibiting serotonin synthesis |
| 02/28/2013 | US20130053335 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine |
| 02/28/2013 | US20130053334 Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| 02/28/2013 | US20130053319 Chemokine derived peptides and uses for chronic wound and angiogenesis inhibition treatments |
| 02/28/2013 | US20130053317 Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| 02/28/2013 | US20130053306 Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis |
| 02/28/2013 | US20130053303 Compounds for enzyme inhibition |
| 02/28/2013 | US20130053301 Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| 02/28/2013 | US20130052737 Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/28/2013 | US20130052279 Reverse micelle system comprising metal ions and use thereof |
| 02/28/2013 | US20130052272 Pharmaceutical compositions and methods for the treatment and prevention of cancer |
| 02/28/2013 | US20130052259 Liposomes comprising amphipathic drugs and method for their preparation |
| 02/28/2013 | US20130052241 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| 02/28/2013 | US20130052217 Tumor vaccination involving a humoral immune response against self-proteins |
| 02/28/2013 | US20130052215 Tumor vaccine |
| 02/28/2013 | US20130052212 Method for allogeneic cell therapy |
| 02/28/2013 | US20130052211 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 02/28/2013 | US20130052207 Prognostic Method for Pulmonary Adenocarcinoma, Pulmonary Adenocarcinoma Detection Kit, and Pharmaceutical Composition for Treating Pulmonary Adenocarcinoma |
| 02/28/2013 | US20130052203 In vivo screening models for treatment of qc-related disorders |
| 02/28/2013 | US20130052199 Molecular Determinants of Myeloma Bone Disease and Uses Thereof |
| 02/28/2013 | US20130052194 Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same |
| 02/28/2013 | US20130052191 Anti-alpha2 integrin antibodies and their uses |
| 02/28/2013 | US20130052184 Gelatinase inhibitors and prodrugs |
| 02/28/2013 | US20130052181 Combined use of ribonuclease and artemisinin |
| 02/28/2013 | US20130052179 Arginine deiminase mutant and preparation and application thereof |
| 02/28/2013 | US20130052170 Grafting material for genetic and cell therapy |
| 02/28/2013 | US20130052165 Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby |
| 02/28/2013 | US20130052160 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| 02/28/2013 | US20130052158 Use of autologous effector cells for treatment of multiple myeloma |
| 02/28/2013 | US20130052157 Use of il-17e for cancer treatment |
| 02/28/2013 | US20130052145 Adhesive slow-release formulations for the local administration of curcumin |
| 02/28/2013 | US20130052142 Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 02/28/2013 | US20130052131 Nanoparticles, methods of making nanoparticles, and methods of use |
| 02/28/2013 | US20130052128 Upar Binding Agents and Methods of Use Thereof |
| 02/28/2013 | US20130052127 Composite body for antigen or drug delivery |
| 02/28/2013 | CA2848726A1 Bax agonist, compositions, and methods related thereto |
| 02/28/2013 | CA2846629A1 Methods and compositions comprising a c-terminalbax peptide |
| 02/28/2013 | CA2846231A1 Inhibitors of nedd8-activating enzyme |
| 02/28/2013 | CA2846092A1 Peg-interferon lambda 1 conjugates |
| 02/28/2013 | CA2846046A1 Bicyclic heteroaromatic compounds |
| 02/28/2013 | CA2845946A1 Fn14-binding proteins and uses thereof |
| 02/28/2013 | CA2845810A1 Anti-ox40 antibodies and methods of using the same |
| 02/28/2013 | CA2844809A1 Combination cancer therapy of hsp90 inhibitor with antimetabolite |
| 02/28/2013 | CA2844729A1 Serine/threonine pak1 inhibitors |
| 02/28/2013 | CA2844540A1 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| 02/28/2013 | CA2844538A1 Bispecific antigen binding molecules |
| 02/28/2013 | CA2844306A1 Anti-tie2 antibodies and uses thereof |
| 02/28/2013 | CA2844143A1 Fc-free antibodies comprising two fab fragments and methods of use |
| 02/28/2013 | CA2844141A1 Anti-mcsp antibodies |
| 02/28/2013 | CA2837975A1 Bispecific t cell activating antigen binding molecules |
| 02/27/2013 | EP2562187A1 Anti-CD37 antibodies |
| 02/27/2013 | EP2562172A1 Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses |
| 02/27/2013 | EP2562159A1 Preparation method of fluoro-substituted deuterated diphenylurea |
| 02/27/2013 | EP2561887A2 Cancer therapy sensitizer |
| 02/27/2013 | EP2561885A2 Use of hades as tumor suppressor target |
| 02/27/2013 | EP2561883A2 Novel vascular endothelial growth factor expression inhibitors |
| 02/27/2013 | EP2561882A2 Novel vascular endothelial growth factor expression inhibitors |
| 02/27/2013 | EP2561881A2 Novel vascular endothelial growth factor expression inhibitors |
| 02/27/2013 | EP2561875A2 Inhibitors of bruton's tyrosine kinase |
| 02/27/2013 | EP2561874A2 Pharmaceutical compositions for treating cancer |
| 02/27/2013 | EP2561871A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| 02/27/2013 | EP2561868A1 Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| 02/27/2013 | EP2561867A1 CDK9 inhibitors in the treatment of midline carcinoma |
| 02/27/2013 | EP2561861A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |